1. Ziemann M, Altermann W, Angert K, Arns W, Bachmann A, Bakchoul T, et al. 2019; Preformed donor-specific HLA antibodies in living and deceased donor transplantation: a multicenter study. Clin J Am Soc Nephrol. 14:1056–66. DOI:
10.2215/CJN.13401118. PMID:
31213508. PMCID:
PMC6625630.
2. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. 2013; Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 95:19–47. DOI:
10.1097/TP.0b013e31827a19cc. PMID:
23238534.
Article
3. Kang H, Yoo J, Lee SY, Oh EJ. 2021; Causes of positive pretransplant crossmatches in the absence of donor-specific anti-human leukocyte antigen antibodies: a single-center experience. Ann Lab Med. 41:429–35. DOI:
10.3343/alm.2021.41.4.429. PMID:
33536364. PMCID:
PMC7884190.
Article
4. Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al. 2012; Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol. 23:2061–71. DOI:
10.1681/ASN.2012070664. PMID:
23160511. PMCID:
PMC3507372.
Article
5. Buttigieg J, Ali H, Sharma A, Halawa A. 2019; Positive Luminex and negative flow cytometry in kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 34:1950–60. DOI:
10.1093/ndt/gfy349. PMID:
30508114.
Article
6. Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, et al. 2021; OPTN/SRTR 2019 annual data report: kidney. Am J Transplant. 21 Suppl 2:21–137. DOI:
10.1111/ajt.16502. PMID:
33595191.
Article
7. Laging M, Gestel JAK, Haasnoot GW, Claas FHJ, van de Wetering J, Ijzermans JNM, et al. 2014; Transplantation results of completely HLA-mismatched living and completely HLA-matched deceased-donor kidneys are comparable. Transplantation. 97:330–6. DOI:
10.1097/01.TP.0000435703.61642.43. PMID:
24202143.
Article
8. Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, et al. 2014; Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant. 14:1573–80. DOI:
10.1111/ajt.12786. PMID:
24913913.
Article
9. Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman AC, et al. 2016; Clinical significance of pretransplant donor-specific antibodies in the setting of negative cell-based flow cytometry crossmatching in kidney transplant recipients. Am J Transplant. 16:3458–67. DOI:
10.1111/ajt.13848. PMID:
27140940.
Article
10. Kwon H, Kim YH, Choi JY, Shin S, Jung JH, Park SK, et al. 2018; Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches. Clin Transplant. 32:e13266. DOI:
10.1111/ctr.13266. PMID:
29676812.
Article
11. Higgins R, Lowe D, Hathaway M, Williams C, Lam FT, Kashi H, et al. 2011; Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation. 92:900–6. DOI:
10.1097/TP.0b013e31822dc38d. PMID:
21968524.
Article
12. Lee H, Lee H, Eum SH, Ko EJ, Min JW, Oh EJ, et al. 2023; Impact of low-level donor-specific anti-HLA antibody on posttransplant clinical outcomes in kidney transplant recipients. Ann Lab Med. 43:325–7. DOI:
10.3343/alm.2023.43.4.364. PMID:
36843405.
Article
13. Chung BH, Choi BS, Oh EJ, Park CW, Kim JI, Moon IS, et al. 2014; Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy. Transpl Int. 27:49–59. DOI:
10.1111/tri.12199. PMID:
24118413.
Article
14. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. 2010; Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 21:1398–406. DOI:
10.1681/ASN.2009101065. PMID:
20634297. PMCID:
PMC2938596.
Article